Shanlai Shangguan
Overview
Explore the profile of Shanlai Shangguan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mosholder A, Izurieta H, Zhang R, Shangguan S, Lu Y, Akhtar S, et al.
Pharmacotherapy
. 2024 Oct;
44(10):803-810.
PMID: 39425479
Background: Concerns have been raised regarding proton pump inhibitor (PPI) use and risk of severe coronavirus disease 2019 (COVID-19). Observational studies have yielded heterogeneous results and were subject to important...
2.
Lloyd P, Lufkin B, Moll K, Ogilvie R, McMahill-Walraven C, Beachler D, et al.
Vaccine
. 2024 Feb;
42(8):2004-2010.
PMID: 38388240
Background: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.)...
3.
Kozlowski S, Tworkoski E, Dharmarajan S, Flowers N, Kwist A, Shangguan S, et al.
Pharmacoepidemiol Drug Saf
. 2024 Feb;
33(2):e5749.
PMID: 38362655
Purpose: Pharmacy chains can differ with respect to the characteristics of their patient populations as well as their nonprescription products, services, and practices, and thus may serve as a surrogate...
4.
Graham D, Izurieta H, Zhang D, Avagyan A, Lyu H, Wiederhorn R, et al.
Am J Med
. 2023 Jul;
136(10):1018-1025.e3.
PMID: 37454868
Background: Alpha-1 adrenergic receptor antagonists prevent cytokine storm in mouse sepsis models. This led to the hypothesis that alpha-1 blockers may prevent severe coronavirus disease 2019 (COVID-19), which is characterized...
5.
Moll K, Lufkin B, Fingar K, Zhou C, Tworkoski E, Shi C, et al.
Vaccine
. 2022 Nov;
41(2):333-353.
PMID: 36404170
Background: The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates...